A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of rhuMAb Beta7 in Patients With Ulcerative Colitis

ClinicalTrials.gov ID: NCT00694980

Public ClinicalTrials.gov record NCT00694980. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 20, 2026, 2:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Intravenous and Subcutaneous rhuMAb Beta7 Administered in a Single-Dose, Dose-Escalation Stage Followed by a Multidose, Parallel-Treatment Stage in Patients With Ulcerative Colitis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a randomized , double-blind, placebo-controlled study of approximately 70 patients with ulcerative colitis.

Study identification

NCT ID: NCT00694980
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Genentech, Inc.; Industry
Enrollment: 48 participants

Conditions and interventions

Conditions

Ulcerative Colitis

Interventions

placebo Drug
rhuMAb Beta7 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 70 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 2008 (Type not available)
Primary completion: Sep 2011 (Actual)
Completion: Sep 2012 (Actual)
Last update posted: Nov 2, 2016

2008 – 2012

United States locations

U.S. sites: 8
U.S. states: 8
U.S. cities: 8

Facility	City	State	ZIP	Site status
Not listed	Anniston	Alabama	36207	—
Not listed	San Francisco	California	94115	—
Not listed	Gainesville	Florida	32610	—
Not listed	Atlanta	Georgia	30308	—
Not listed	Lexington	Kentucky	40536	—
Not listed	Rochester	Minnesota	55905	—
Not listed	Great Neck	New York	11021	—
Not listed	Chapel Hill	North Carolina	27599	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00694980, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 2, 2016 · Synced Oct 20, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00694980 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →